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Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are
increasingly common cause of chronic liver disease worldwide. The diagnosis of NASH
is challenging as most affected patients are symptom-free and the role of routine screen-
ing is not clearly established. Most patients with severe obesity who undergo bariatric
surgery have NAFLD, which is associated insulin resistance, type 2 diabetes mellitus
(T2DM), hypertension, and obesity-related dyslipidemia.The effective treatment for NAFLD
is weight reduction through lifestyle modifications, antiobesity medication, or bariatric
surgery. Among these treatments, bariatric surgery is the most reliable method for achiev-
ing substantial, sustained weight loss. This procedure is safe when performed by a skilled
surgeon, and the benefits include reduced weight, improved quality of life, decreased
obesity-related comorbidities, and increased life expectancy. Further research is urgently
needed to determine the best use of bariatric surgery with NAFLD patients at high risk
of developing liver cirrhosis and its role in modulating complications of NAFLD, such as
T2DM and cardiovascular disease.The current evidence suggests that bariatric surgery for
patients with severe obesity decreases the grade of steatosis, hepatic inflammation, and
fibrosis. However, further long-term studies are required to confirm the true effects before
recommending bariatric surgery as a potential treatment for NASH.
Keywords: non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, obesity, diabetes, bariatric surgery,
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INTRODUCTION
In recent years, the obese population has been rapidly increasing
because of increases in diets rich in saturated fat and processed
carbohydrates and sedentary lifestyles. The metabolic syndromes
that are considered risk factors of arteriosclerotic diseases, such
as abnormal glucose tolerance, hyperlipemia, and hypertension,
have increased alongside obesity in the developed world (1).
Non-alcoholic fatty liver disease (NAFLD) is a liver phenotype
of metabolic syndrome. Factors that affect the morbidity of this
disease include genetic background, an epigenetic control mech-
anism, the fat toxicity of free fatty acid, and a natural immunity
system of intestinal bacteria. Based on current trends, the rate of
obesity in the US is projected to reach approximately 40% by 2025
(2). However, the prevalence of NAFLD is not well known, though
it is estimated at 6.3–33% worldwide. In North America, the preva-
lence of NAFLD is estimated at about 20%,and the prevalence of its
more progressive subtype, non-alcoholic steatohepatitis (NASH),
is approximately 2–3% (3–6).
Non-alcoholic fatty liver disease is the most common cause of
liver dysfunction worldwide, and obesity is a well-documented
risk factor for the disease. It is highest in populations with pre-
existing metabolic conditions, such as obesity, T2DM, and dys-
lipidemia (7). NASH is often an incidental diagnosis and can be
associated with other disease processes, such as hypopituitarism,
hypogonadism, hypothyroidism, polycystic ovarian syndrome,
and obstructive sleep apnea syndrome. It is also frequently
associated with pancreatoduodenal resections (8).
Perioperative liver biopsy in patients with severe obesity can
result in complications, such as bleeding and sampling error, mak-
ing exact diagnosis difficult to achieve. Among patients with severe
obesity undergoing bariatric surgery, the prevalence of NAFLD can
exceed 90%, and up to 5% of these patients may have unsuspected
cirrhosis. Bariatric surgery can improve obesity-related diseases in
addition to reducing body weight; as a result, it has more recently
been termed “metabolic surgery.”
We conducted a literature review using the Medline database.
We identified studies conducted between 1995 and 2014 that
examined the impact of bariatric surgery on NAFLD. This review
evaluates the benefits and potential treatment option of bariatric
surgical procedures for NAFLD as described in the literature.
MEDICAL TREATMENT OF NAFLD
Past studies investigating lifestyle changes, such as diet, exercise,
and behavior modification that resulted in weight loss of 5–10%,
have shown that these changes can improve steatosis in some
patients (7, 9). Greater weight loss of at least 10% has also been
shown to improve inflammation. However, it is important to note
that adherence to lifestyle interventions can be problematic. In
several studies, only 15% of patients achieved a weight loss >10%,
and most of these people regained the weight. The best average
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weight loss among participants has been reported at 3–4 kg at 2
and 4 years (10).
Although no drugs are specifically licensed for the treatment
of NAFLD, there is evidence to support the use of selected agents.
Antiobesity medications such as orlistat, and drugs that augment
insulin sensitivity and reduce plasma glucose concentrations and
oxidative stress such as thiazolidinediones and metformin are
among those that have been shown to improve liver histology in
NAFLD (11–14). Orlistat inhibits enteric lipid absorption and has
been promoted as a weight loss aid. It has also been evaluated as a
potential therapy for NASH (15).
It is thought that GLP-1 receptor agonists work toward
improvement of insulin resistance because not only can they
improve the effect of insulin secretion but can also promote glu-
cose uptake by the liver, adipose tissue, and skeletal muscle (16).
Many studies have reported improvement outcomes with GLP-1
receptor agonist therapy in animal NAFLD models and NAFLD
patients, and the expectation of this drug’s effectiveness to treat
NAFLD is increasing (17–19). According to a recent systematic
review and meta-analysis, GLP-1 receptor agonists significantly
decreased the weight of obese patients regardless of the exis-
tence of T2DM (20). Astrup et al. planned a clinical study of the
GLP-1 receptor agonists to treat severely obese patients without
T2DM. These researchers reported that weight loss was signifi-
cantly greater in the patients treated with GLP-1 receptor agonists
than in the patients with only diet and exercise modifications.
These results showed better outcomes than in the patients with
orlistat as a comparative drug (21). Thus, the use of pharmaco-
logical agents for obesity is quickly gaining popularity for patients
with mild obesity and visceral adipose obesity. Incretin mimet-
ics may therefore represent a novel therapeutic option in the
future for slowing the progression of NAFLD. However, larger
studies with longer treatment durations are required to confirm
whether incretin mimetics confers any benefits above their effects
on weight loss.
BARIATRIC SURGERY AND NAFLD
The goal of bariatric surgery is not only to achieve satisfactory
weight loss but also to obtain improvements in obesity-related
comorbidities, including T2DM, obstructive sleep apnea syn-
drome, hyperlipidemia, and hypertension. However, no random-
ized controlled trials examining the effects of bariatric surgery on
NAFLD were found in the literature search. Two meta-analyses
evaluated the effect of bariatric surgery on the liver histology of
patients with NAFLD (22, 23). Mummadi et al. reported that the
improvement or resolution rates of steatosis, steatohepatitis, and
fibrosis of 15 studies and 766 paired liver biopsies after bariatric
surgery were 91.6, 81.3, and 65.5%, respectively (22). Complete
resolution of NASH was archived in 69.5% of patients. However, a
recently published Cochrane review concluded that the lack of
randomized clinical trials or quasi-randomized clinical studies
has prevented a definitive assessment of the benefits and harms
of bariatric surgery as a therapeutic approach for patients with
NASH (23).
ROUX-EN-Y GASTRIC BYPASS
Bariatric surgery has a positive effect on obesity-related diseases
in addition to reducing body weight. Because of this, it has been
more recently termed metabolic surgery. Roux-en-Y gastric bypass
(RYGB) has a reportedly greater positive effect on T2DM than
restrictive procedures. This mechanism is not understood; how-
ever, two theories exist: the hindgut and foregut hypotheses. In the
hindgut hypothesis, bypass of the upper small intestine diverts
food directly to the lower small intestine, where glucagon-like
peptide-1 (GLP-1) secretory cells promote GLP-1 secretion. In the
foregut hypothesis, an unknown glucose-tolerance-complicating
factor that inhibits GLP-1 secretion is discharged from the upper
small intestine; because bypass surgery prevents food from pass-
ing through the upper small intestine, this factor is no longer
secreted (24, 25). Post-operatively, patients who undergo RYGB
have shown a marked reduction in hepatic lipid content and
improved hepatic insulin sensitivity well before significant weight
loss occurs. These benefits to the liver are directly related to at
least two enteroendocrine cells-synthesized gut peptides GLP-1
and peptide YY (26–29).
No randomized clinical trials of bariatric surgery in NAFLD
were found in the literature. Fourteen studies including reviews
showed that RYGB has been associated with improvement in
NAFLD (11, 28, 30–42) (Table 1). Overall, RYGB in obese patients
has decreased the grade of steatosis, hepatic inflammation, and
fibrosis. However, some studies reported a few patients with
worsening or new fibrosis (30, 32, 33, 35, 37).
SLEEVE GASTRECTOMY AND GASTRIC BANDING
Recent studies have shown that laparoscopic sleeve gastrec-
tomy (LSG) is safe and effective, resulting in weight loss some-
where between the rates of laparoscopic RYGB and laparoscopic
adjustable gastric banding (LAGB) (43, 44). Although LSG is a
restrictive procedure, the removal of the gastric fundus, the pri-
mary site of ghrelin production, appears to have a hormonal effect
that enhances weight loss by reducing appetite (25).
Based on questionnaire survey results from 50 countries, Buch-
wald et al. reported that 340,768 bariatric surgeries were per-
formed worldwide in 2011 (45), which included 47% LRYGB, 28%
LSG, and 18% LAGB. LSG, an initial bariatric surgery for severely
obese patients, is a technique used to lower the rates of compli-
cation and surgical death. For these reasons, LSG has increased
rapidly worldwide and is predicted to become the most frequently
performed bariatric surgery.
Only four studies were found that utilized LAGB or LSG as
a restrictive procedure to examine the effects on NAFLD (46–
49) (Table 2). Dixon et al. conducted paired liver biopsies on
36 obese patients – the first at the time of LAGB and the sec-
ond after weight loss. On follow-up biopsies at 25.6 months after
LAGB, the mean percentage of excess weight loss was 52%, and
there were major improvements in lobular steatosis, necroin-
flammatory changes, and fibrosis. However, portal abnormalities
remained unchanged (46). The same author examined a second
similar investigation of 60 severely obese patients after LAGB. On
follow-up biopsies at 29.5 months after LAGB, only 10% displayed
NASH. Improvements in steatosis, inflammation, and fibrosis, as
well as in biochemical markers of liver function, were seen in
all of the patients. The researchers concluded that decreases in
gamma-glutamyl transferase concentrations were associated with
histological improvement (47). Mathurin et al. reported no signif-
icant differences among LAGB, RYGB, and biliointestinal bypass
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Table 1 | Effect of RYGB on NAFLD.
Reference Patients Types of study Main outcomes (improvement) Follow-up (months)
Silverman et al. (30) 91 Retro Steatosis and fibrosis 18.4
Mattar et al. (31) 70 Pros Steatosis and fibrosis 15
Clark et al. (32) 16 Pros Steatosis, inflammation, and fibrosis 0.8
Mottin et al. (33) 90 Retro Steatosis (82%) 12
Klein et al. (34) 7 Pros Fibrosis and inflammation 12
Barker et al. (28) 19 Pros Steatosis, inflammation, and fibrosis 21.4
Csendes et al. (35) 16 Pros Histology (80%) 22
de Almeida et al. (36) 16 Pros Steatosis, inflammation, and fibrosis 23.5
Furuya et al. (37) 18 Pros Steatosis and fibrosis 24
Liu et al. (38) 39 Retro Steatosis, inflammation, and fibrosis 18
Weiner et al. (39) 116 Retro Complete regression (83%) 18.6
Meretto et al. (40) 78 Retro Resolved fibrosis (50%) Unavailable
Vargas et al. (41) 26 Pros Steatosis, inflammation, and fibrosis 16
Tai et al. (42) 21 Pros Steatosis, inflammation, and fibrosis 12
Pros, prospective; Retro, retrospective.
Table 2 | Effect of restrictive bariatric surgery on NAFLD.
Reference Patients Types of surgery Main outcomes (improvement) Follow-up (months)
Dixon et al. (46) 36 LAGB Steatosis, inflammation, and fibrosis 25.6
Dixon et al. (47) 60 LAGB Steatosis, inflammation, and fibrosis 29.5
Mathurin et al. (48) 381 LAGB Steatosis 50
Karcz et al. (49) 236 LSG AST, ALT, triglyceride and HDL levels 12
Pros, prospective; Retro, retrospective.
groups, and those who progressed to fibrosis became more insulin
resistant. Five years after bariatric surgery for severe obesity, almost
all of the patients had low levels of NAFLD, whereas fibrosis slightly
increased (48).
Studies of follow-up biopsies for NAFLD in LSG were not found
in the literature review. Karcz et al. reported on the effect on NASH
diagnosed at the time of LSG and NASH-related comorbidities
using clinical and biological data at 1- and 3-year follow-ups. A
significant improvement of AST, ALT, triglyceride, and HDL levels
was shown in the 87 NASH patients (49).
As a mechanism that improves NAFLD, GLP-1 plays an impor-
tant role after LSG. It has been shown that GLP-1 receptor agonists
may be an effective tool for the treatment of NASH. This is due to
the continuous increase of serum GLP-1 levels and the reduction
of hepatic glucose production, which are expected indirect actions
of GLP-1 after LSG. However, a future study is required to confirm
this. Umemura et al. reported that the mean weight reduction was
11 kg at 1 month after LSG for patients with severe obesity; the
mean GLP-1 levels increased, while mean ghrelin levels decreased
significantly (50). The researchers also reported that the changes in
these hormones might have derived from a resection of the gastric
fundus and the hindgut effect with accelerated gastric emptying.
BILIOPANCREATIC DIVERSION PROCEDURE
Only two studies were found the biliopancreatic diversion pro-
cedures to evaluate the effects on NAFLD (51, 52). Keshishian
et al. studied repeat liver biopsies on 78 patients after a duode-
nal switch procedure. Hepatic inflammation slightly worsened at
6 months, but improvements were seen at and beyond 12 months.
By 36 months, the histological degree of steatosis had improved by
60% and the severity of inflammation improved by three grades
(51). Kral et al. studied liver biopsies on 104 patients after a
biliopancreatic diversion procedure. Steatosis grades decreased
in correlation with weight loss as expected, but the researcher
observed a post-operative increase in fibrosis in 40% of the
patients, a decrease in 27%, and no change in 33% (52). The
researcher suggested that several factors such as alcohol, bacte-
rial products, iron storage, deficiencies of antioxidants, protein,
lipotropic factors, or the generation of reactive oxygen species
might explain the development or lack of improvement in a few
patients with severe fibrosis or cirrhosis.
BARIATRIC SURGERY AS A POTENTIAL TREATMENT
FOR NAFLD
The current hypothesis for the development of NAFLD is that obe-
sity and insulin resistance increase the release of free fatty acids
from adipocytes (53), and hepatic insulin resistance and hepatic
steatosis precede the development of T2DM (54).
Bile acids are important regulators of energy balance through
the unclear receptor farmesoid X receptor (FXR) and the G-
protein-coupled membrane receptor TGR5. Activation of FXR by
bile acids after a meal induces synthesis of the intestinal peptide
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FIGURE 1 | Potential mechanisms or improvement for NAFLD after bariatric surgery.
hormone FGF-19 and triggers a cascade that controls fed-fasted
state metabolism. Bile acids could also promote weight loss by
increasing energy expenditure in brown adipose tissue via TGR5.
Bile acids might be involved in bariatric surgery-induced changes
in energy homeostasis through two mechanisms: increased secre-
tion of bile acids with direct effects on energy balance and
increased delivery to the distal intestine due to nutrient and bile re-
routing, with increased stimulation of L-cell production and the
release of hormones with attenuating effects on bariatric surgery
(55). Patti et al. reported that total serum bile acid concentra-
tions were higher in RYGB patients than in obese patients (56).
Haluzíková et al. reported that the effects of LSG on serum concen-
trations of FGF-19 and FGF-21 along with circulating bile acids
and other relevant hormonal and biochemical parameters (57).
The researchers concluded that increased FGF-19 and decreased
ghrelin concentrations could have partially contributed to the
improvement of systemic inflammation and some metabolic para-
meters after LSG, while changes of FGF-21 are rather secondary
because of weight loss. Pournaras et al. reported that gastric bypass
leads to increased plasma bile acids, FGF-19, incretin, and satiety
gut hormone concentrations (58).
In a recent systematic review, post-operative resolution or
improvement of T2DM occurred in 73% of patients (59). Poten-
tial mechanisms of T2DM remission underlying the direct anti-
diabetic impact of bariatric surgery include enhanced nutrient
stimulation of GLP-1, altered physiology from excluding ingested
nutrients from the upper intestine, compromised ghrelin secre-
tion, improved hepatic insulin sensitivity,and improved peripheral
insulin sensitivity. The changes in the rate of eating, gastric empty-
ing, intestinal transit time,nutrient absorption,and sensing,as well
as bile acid metabolism, may also be implicated (60, 61). Bariatric
surgery, which offers the effects of metabolic surgery, should be
considered for T2DM patients having difficulty continuing with
medical treatment and a potential for future deterioration and
diabetic complications.
The mechanism of how bariatric surgery plays a role as a poten-
tial treatment for NAFLD is also complex and not fully understood.
Bariatric surgery is likely to have potential benefits in ameliorating
the factors such as insulin resistance, lipid profile, inflammation,
weight loss, and adipokines that contribute in a marked way to the
pathogenesis of NAFLD (Figure 1).
CURRENT GUIDELINES
Currently, the only proven effective treatment for NAFLD is weight
loss. Many reports have shown that when performed by a skilled
surgeon, bariatric surgery is safe and effective for reducing weight,
improving quality of life, decreasing obesity-related diseases, and
increasing life expectancy. However, there is a lack of random-
ized controlled trials examining the effects of bariatric surgery
on NAFLD; the only available studies are either retrospective or
prospective cohort studies (5).
The American Association for the Study of Liver Diseases
(AASLD), American College of Gastroenterology (AGG), and
American Gastroenterological Association (AGA) recommend
that foregut bariatric surgery should not be contraindicated in
otherwise eligible obese individuals with NAFLD or NASH. How-
ever, these organizations recognize that it is premature to con-
sider foregut bariatric surgery as an established option to treat
NASH (5).
CONCLUSION
The current evidence suggests that bariatric surgery for patients
with severe obesity decreases the grade of steatosis, hepatic inflam-
mation, and fibrosis. However, the lack of randomized clinical
trials demonstrating the beneficial effects of bariatric surgery
procedures for treatment of NAFLD prevented us from reach-
ing a scientifically sustained conclusion. Positive results have been
observed in cohort studies; however, this research has a high risk
of bias. The research also reported a potential risk for worsening
fibrosis scores. Therefore, bariatric surgery must be assessed in
randomized clinical trials.
The mechanism of bariatric surgery’s role as a potential treat-
ment for NASH is complex and not fully understood. Fur-
ther long-term studies are required to confirm the true effects
before recommending bariatric surgery as a treatment option
for NASH.
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